Cardiol Therapeutics shares rise 2.86% premarket after Ionis Pharmaceuticals' positive CHMP opinion for TRYNGOLZA®.

Cardiol Therapeutics Inc. rose 2.86% in premarket trading. The positive movement in the stock price is likely due to the news that Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4 2025.